SEC Form 4	
------------	--

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

( ) ) /	
OMB Number:	3235-0287
Estimated average b	ourden
hours per response:	0.5

I

to Section 16. Form 4 or Form 5	Filed pursuant to Section 16(a) of the Securities Exchange Act of 193	Estimated average burden		
obligations may continue. See	or Section 30(h) of the Investment Company Act of 1940	hours per response: 0.		
1. Name and Address of Reporting Person*	2. Issuer Name <b>and</b> Ticker or Trading Symbol	(Check all applicat	10% Owner	
Thorp_Clay	<u>Clearside Biomedical, Inc.</u> [ CLSD ]	X Director		
(Last) (First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year)	- Officer (gi	ive title Other (specify below)	
C/O CLEARSIDE BIOMEDICAL, INC.	02/10/2021	below)		
900 NORTH POINT PARKWAY, SUITE 200 (Street) ALPHARETTA GA 30005	4. If Amendment, Date of Original Filed (Month/Day/Year) 02/10/2021	Line) X Form filed	nt/Group Filing (Check Applicable d by One Reporting Person d by More than One Reporting	
(City) (State) (Zip)				

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)	ction	4. Securities A Disposed Of ( 5)				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130. 4)
Common Stock	02/10/2021		<b>S</b> <sup>(1)</sup>		32,873(2)	D	<b>\$</b> 4. <b>4</b> 3 <sup>(3)</sup>	4,951,547 <sup>(4)</sup>	D	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on March 16, 2020.

2. Consists of (i) 447 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 21,095 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 1,916 shares sold by Hatteras Venture Affiliates III, LP ("HVA III") and (iv) 9,415 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").

3. This transaction was executed in multiple trades at prices ranging from \$4.40 to \$4.50, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

4. The original Form 4 inadvertently misstated the total number of shares. This reflect the accurate number of shares beneficially owned.

## Remarks:

/s/ Mark Ballantyne, Attorney-12/19/2022 in-Fact for Clay Thorp

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.